Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Denali Therapeutics (DNLI) Non-cash Items (2017 - 2018)

Denali Therapeutics has reported Non-cash Items over the past 2 years, most recently at $1.5 million for Q1 2018.

Quarterly Non-cash Items changed N/A to $1.5 million in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Mar 2018, changed N/A year-over-year, with the annual reading at $77.3 million for FY2017, N/A changed from the prior year.
Non-cash Items was $1.5 million for Q1 2018 at Denali Therapeutics, down from $77.3 million in the prior quarter.
Over five years, Non-cash Items peaked at $77.3 million in Q4 2017 and troughed at $1.5 million in Q1 2018.